Clinical Trials Logo

Ovarian Function Insufficiency clinical trials

View clinical trials related to Ovarian Function Insufficiency.

Filter by:

NCT ID: NCT05489367 Completed - Fertility Disorders Clinical Trials

Does COVÄ°D-19 m-RNA Vaccine Affect Fertility and Over Reserve ?

Start date: February 1, 2022
Phase:
Study type: Observational [Patient Registry]

Women's ovarian reserve and fertility were compared before and after 2 doses of vaccination

NCT ID: NCT05330130 Recruiting - Infertility Clinical Trials

Impact of FSH Dosage During Ovarian Stimulation for IVF/ICSI in Granulosa Cells

Start date: July 5, 2023
Phase: Phase 1
Study type: Interventional

To study the influence of different daily rec-FSH dosages (150 IU versus 300 IU), performed in the same patient in consecutive cycles, on the relation between FSH- and LH-receptors of the granulosa cells of the growing follicle.

NCT ID: NCT02933190 Not yet recruiting - Clinical trials for Magnetic Resonance Imaging

Fertility After Transvaginal Surgery or Uterine Artery Embolization Combined With Uterine Curettage in Patients With Cesarean Scar Pregnancy

Start date: November 2016
Phase: N/A
Study type: Interventional

To investigate the fertility in patients after treatment by transvaginal surgery or uterine artery embolization combined with uterine curettage

NCT ID: NCT02855827 Recruiting - Clinical trials for Ovarian Function Insufficiency

Constitution of a Cohort for Monitoring Patients Candidating for Ovarian Tissue Autograft

PERIDATOR
Start date: May 2013
Phase:
Study type: Observational

Ovarian cryopreservation is one of the available option for preserving fertility prior to potentially sterilizing treatments. In the absence of other techniques such as in vitro folliculogenesis or injection of isolated ovarian follicles, this tissue can only be re-used by autograft. In France, the first live birth after orthotopic ovarian transplantation, was obtained by Roux et al. in 2009. This clinical trial aims to build a cohort of patients likely to use their ovarian tissue cryopreserved by autograft.

NCT ID: NCT02846064 Recruiting - Clinical trials for Ovarian Function Insufficiency

Development of Ovarian Tissue Autograft in Order to Restore Ovarian Function

DATOR
Start date: October 2013
Phase: N/A
Study type: Interventional

Ovarian cryopreservation is one of the available option for preserving fertility prior to potentially sterilizing treatments. In the absence of other techniques such as in vitro folliculogenesis or injection of isolated ovarian follicles, this tissue can only be re-used by autograft. In France, the first live birth after orthotopic ovarian transplantation, was obtained by Roux et al. in 2009. This clinical trial aims to collect data on the efficiency of the graft in terms of restoration of ovarian function and live births. It will also allow us to carry out the patient follow-up after ovarian tissue cryopreservation and after autograft when achieved. In cases of neoplastic malignancies, minimal residual disease detection will be performed on ovarian tissue, to avoid any risk of cancer re-seeding.

NCT ID: NCT02132390 Not yet recruiting - Breast Cancer Clinical Trials

Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea

Start date: May 2014
Phase: Phase 3
Study type: Interventional

Compare the potential benefits of adjuvant toremifene with or without goserelin in premenopausal women with stage I-IIIA, hormonal receptor positive breast cancer accompanied with or without chemotherapy induced amenorrhoea.

NCT ID: NCT01782807 Unknown status - Clinical trials for Ovarian Function Insufficiency

Ovarian Function After Hysterectomy With or Without Fimbriectomy or Salpingectomy

Start date: October 2011
Phase: N/A
Study type: Interventional

The impact of Hysterectomy with preservation of the ovaries on ovarian function has long been controversial. studies have shown conflicting data regarding ovarian function after simple Hysterectomy. In recent years, there is a growing evidence that Salpingectomy or Fimbriectomy may have preventive value reducing Ovarian and Primary Peritoneal carcinoma, but the safety and the consequences regarding ovarian function have yet to be established. The aim of this study is to evaluate ovarian function after Hysterectomy alone Vs. Hysterectomy combined with salpingectomy or fimbriectomy

NCT ID: NCT00888082 Withdrawn - Breast Cancer Clinical Trials

Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With Chemotherapy

PROOF
Start date: n/a
Phase: Phase 3
Study type: Interventional

Primary objective of this study is to determine the effectiveness of goserelin acetate (Zoladex) in preserving ovarian function in premenopausal women undergoing adjuvant chemotherapy for primary invasive breast cancer by documenting persistence or resumption of regular menses via menstrual history, serum FSH and E2 measurements. The secondary objectives of this study are as follows: To investigate the impact of treatment with chemotherapy with or without goserelin acetate (i.e. impact of the expectation of ovarian function preservation) on participants' quality of life (QOL) by FACT-ES scale, and to compare safety and tolerability of study drugs in two treatment groups by evaluation of adverse events.

NCT ID: NCT00507780 Withdrawn - Ovarian Function Clinical Trials

Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy

Start date: July 18, 2007
Phase: Phase 4
Study type: Interventional

This study will examine whether the drug cetrorelex acetate (Cetrotide[Registed Trademark]) can protect ovarian function in women undergoing chemotherapy. Some cancer treatments are known to cause a change in women's periods or to cause menstruation to stop completely, so that they cannot become pregnant. Cetrorelex acetate has been used for many years to lower hormone levels and stop periods in patients undergoing in vitro fertilization treatments. This study will see if making the ovaries inactive may protect them from being affected by certain cancer drugs, and thus preserve fertility. Women up to age 21who have begun menstruating, who have their uterus and at least one functioning ovary, and who are undergoing chemotherapy with cyclophosphamide, busulfan, nitrogen mustard or L-phenalanin mustard may be eligible for this study. Participants undergo the following procedures during this 24-month study: Baseline evaluation - Medical history, physical examination and blood and urine tests - Questionnaire about quality of life, menstrual periods, vaginal bleeding and desire for future fertility - 3D ultrasound of abdomen - DEXA scan to evaluate bone density Assignment to treatment with: - Lo ovral (contraceptive pill to prevent pregnancy and control menstrual periods) alone, or - Lo ovral and the study drug cetrorelex acetate, given as an injection under the skin once a day for six menstrual cycles Evaluations - Transvaginal 3D ultrasound to monitor changes in the ovary - after 6 months of cetrorelex acetate injections - DEXA scan - after 6 months of cetrorelex acetate injections - Blood tests for safety monitoring, pregnancy testing, endocrine tests and research uses - every 3 months during first year, every 6 months during second year - Questionnaire to monitor changes and quality of life - every 3 months during first year, every 6 months during second year.

NCT ID: NCT00429494 Completed - Clinical trials for Premature Ovarian Failure

GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients

Start date: November 2002
Phase: Phase 2
Study type: Interventional

Primary Objectives: - To determine the effectiveness of the 3-month depot leuprolide in inducing and maintaining secondary amenorrhea in patients undergo hematopoietic stem cell transplantation. - To determine the incidence of regained ovarian function manifested as spontaneous restoration of menstruation and normalization of hormonal level in patients after transplantation and discontinuation of long-acting leuprolide.